Study Design We screened 573 patients at 43 sites in the usa. Of these individuals, 227 were randomly assigned in a 1:1:1:1 ratio to receive placebo or oral bardoxolone methyl at a dose of 25, 75, or 150 mg once daily for 52 several weeks . The analysis had four intervals: a 21-day screening period; an 8-week amount of dose adjustment that may be extended up to 20 weeks if needed to reach the randomly assigned dose of bardoxolone methyl; dose maintenance from the ultimate end of the dose-adjustment period through week 52; and follow-up for four weeks after the last dose.Thus, conditions can be defined in which conventional immunoperoxidase staining of a standard biopsy sample of right ventricular endomyocardium may be used as a diagnostic check for ARVC. Such a check could be performed in most pathology departments in which immunoperoxidase has turned into a standard approach to tissue diagnostics. Our results are promising when it comes to developing a particular and sensitive immunohistochemical check for the medical diagnosis of ARVC.